ENVVENO MEDICAL CORP (NVNO) Stock Analyst Earnings Estimates
NASDAQ:NVNO - Nasdaq - US29415J1060 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 420K -46.84% | 190K -54.76% | 30K -84.21% | -100.00% | 7.14M | 17.136M 140.00% | 29.294M 70.95% | ||||||
| EBITDA YoY % growth | -5.97M -32.37% | -7.4M -23.95% | -6.97M 5.81% | N/A -29.70% | N/A -85.18% | N/A -47.67% | N/A 1.08% | N/A 4.02% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -6.11M -31.12% | -7.53M -23.24% | -7.09M 5.84% | -7.181M -28.91% | -12.842M -84.79% | -25.724M -47.60% | -27.234M -0.28% | -23.735M 4.00% | -24.235M -0.98% | -24.317M -0.34% | -19.523M 19.71% | -12.362M 36.68% | |
| Operating Margin | -1,454.76% | -3,963.16% | -23,633.33% | N/A | N/A | N/A | N/A | N/A | N/A | -340.57% | -113.93% | -42.20% | |
| EPS YoY % growth | N/A | N/A | N/A | -0.35 97.22% | -1.40 -465.17% | -2.25 -11.73% | -2.11 10.50% | -1.35 35.20% | -1.10 13.26% | -1.02 7.41% | -0.75 26.00% | -0.48 36.49% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.31 12.57% | -0.29 4.80% | -0.24 -11.27% | -0.23 28.91% | -0.22 26.67% | -0.14 50.00% |
| Revenue Q2Q % growth | 510K | 4.814M | 6.283M | 8.486M | ||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.722M -8.94% | -6.497M 3.01% | -5.824M -17.57% | -5.6M 20.56% | -5.457M 18.82% | -3.315M 48.98% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.33 -6.45% | -0.29 | -0.04 | -15.55% |
| Q1 2025 Q2Q % growth | -0.22 29.03% | -0.35 | 0.13 | 36.56% |
| Q4 2024 Q2Q % growth | -0.30 16.67% | -0.36 | 0.06 | 15.97% |
| Q3 2024 Q2Q % growth | -0.35 22.22% | -0.34 | -0.01 | -3.98% |
| Q2 2024 Q2Q % growth | -0.31 46.55% | -0.37 | 0.06 | 15.58% |
| Q1 2024 Q2Q % growth | -0.31 45.61% | -0.41 | 0.10 | 24.02% |
| Q4 2023 Q2Q % growth | -0.36 34.55% | -0.47 | 0.11 | 23.27% |
| Q3 2023 Q2Q % growth | -0.45 16.67% | -0.49 | 0.04 | 8.09% |
| Q2 2023 Q2Q % growth | -0.58 7.94% | -0.50 | -0.08 | -16.05% |
| Q1 2023 Q2Q % growth | -0.57 -21.28% | -0.49 | -0.08 | -16.42% |
| Q4 2022 Q2Q % growth | -0.55 41.49% | -0.58 | 0.03 | 5.40% |
| Q3 2022 Q2Q % growth | -0.54 -107.69% | -0.53 | -0.01 | -1.81% |
| Q2 2022 Q2Q % growth | -0.63 -125.00% | -0.34 | -0.29 | -87.17% |
| Q1 2022 Q2Q % growth | -0.47 2.08% | -0.30 | -0.17 | -58.89% |
| Q4 2021 Q2Q % growth | -0.94 61.79% | -0.34 | -0.60 | -179.26% |
| Q3 2021 Q2Q % growth | -0.26 79.20% | -0.35 | 0.09 | 25.03% |
| Q2 2021 Q2Q % growth | -0.28 | -0.35 | 0.07 | 19.26% |
| Q1 2021 Q2Q % growth | -0.48 | -0.35 | -0.13 | -38.41% |
| Q4 2020 Q2Q % growth | -2.46 24.31% | -1.00 | -1.46 | -146.10% |
| Q3 2020 Q2Q % growth | -1.25 50.00% | -1.28 | 0.02 | 1.96% |
| Q4 2019 Q2Q % growth | -3.25 | -3.32 | 0.06 | 1.96% |
| Q3 2019 Q2Q % growth | -2.50 | -3.57 | 1.07 | 29.97% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2020 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 3.23% | 0% | 11.48% |
| Revenue | N/A | -100% | N/A | -100% |